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Genetic testing
aided by the discovery in 1998 that the vast majority MRTs (including
those in the brain, called atypical teratoid/rhabdoid tumors [AT/RTs])
harbor deleterious mutations in the SWI/SNF chromatin remodeling
gene SMARCB1 (also called INI1), which are accompanied by loss of pro-
tein expression in the tumor (Biegel et al., 2014). It was later discovered
that those without SMARCB1 alteration have mutations in and loss of
expression of its SWI/SNF partner, SMARCA4 (also called BRG1) (Biegel
et al., 2014). Until recently, however, it was not appreciated that MRTs
in the ovary (where the differential diagnosis of such tumors is broad)
are caused by mutations in the same gene as another rare ovarian
tumor called “small cell carcinoma of the ovary, hypercalcemic type”(MRTOs) and SCCOHT are in fact the same entity and should all be
Introduction
Malignant rhabdoid tumors (MRTs) are rare soft tissue tumors that
often present in childhood and arise most commonly in the kidney;
they can arise in extra-renal sites and in adults, albeit rarely. MRTs were
ﬁrst introduced by Beckwith and Palmer as a “rhabdomyosarcomatoid
variant of Wilms tumor” in 1978 to describe a rare, pediatric aggressive
neoplasia of the kidney, but after they were seen in extra-renal sites
and in adults, and ultrastructural and immunohistochemical investiga-
tions failed to show the myogenic origin of this tumor, it was renamed
“malignant rhabdoid tumor” (Foulkes et al., 2014).
MRTs are rare in the female genital tract, but when they do arise,
diagnoses are difﬁcult and equivocal at times, treatment is undeﬁned,
and they carry a grave prognosis. When confronted with a likely MRT,
physicians face two main challenges: substantiating the diagnosis andnetics, Lady Davis Institute and
iversity, Montreal, QC H3T1E2,
es).
. This is an open access article underestablishing treatment strategies. This diagnostic challenge was greatly
(SCCOHT), which show inactivating mutations in SMARCA4, accompa-
nied by loss of expression of the protein (Jelinic et al., 2014; Ramos
et al., 2014a; Witkowski et al., 2014). On the basis of their genetic and
histological similarity, it was proposed that MRTs of the ovary
named MRTO (Foulkes et al., 2014). In this context, it should be noted
that the previously reported “large cell variant” of SCCOHT is a type of
“pure rhabdoid” SCCOHT.
MRTs have been reported in the gynecological tract: twelve cases
have been described in the vulva, ten cases in the uterus, one in the uter-
ine cervix, and two in the ovaries (Banzai et al., 2007; Narendra et al.,
2010; Tsuda et al., 2001). Herewe present an unusual case of an ovarian
tumor diagnosed as, prior to genetic analysis, a primary pureMRTO.We
discuss how genetic analysis, despite being carried out after the death of
the affected woman, has important implications for classiﬁcation of
MRTs and highlights that germ-linemutations are not rare in apparent-
ly isolated cases of SCCOHT/MRTO. This patient's children could be of-
fered genetic counseling and possible genetic testing in the future.Case report
Clinical presentation and operative interventions
A 34-year-old gravida 4 para 4woman presented in 2010with a one
month history of left lower abdominal pain. Physical exam revealed a
large irregular mobile pelvic mass. Ultrasound showed an 11 × 8 cm
irregular hyper-echogenic complex mass with abundant blood ﬂowthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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erate right hydro-ureteronephrosis secondary to the pelvic mass. No
disease was seen at other sites. Tumor markers CA 19-9, CEA, CA 15-3,
AFP, HCG, and LDH were within normal limits. CA-125 was slightly
elevated at 62 U/ml. The patient underwent explorative laparotomy and
frozen sections of the right affected 16 × 12 × 6 cm ovary revealed an un-
differentiated carcinoma. Maximal debulking was performed, including
total abdominal hysterectomy, bilateral salpingo-oophorectomy,
bilateral pelvic and para-aortic lymphnode dissection, and omentectomy.
The tumor replaced the right ovary and extended to involve the right
common iliac lymph nodes and omentum.
Histopathology and initial immunohistochemistry
Typical features of MRTO were observed. The tumor was composed
of sheets of large round to polygonal atypical cells with large nuclei,
prominent nucleoli, and abundant eosinophilic cytoplasm (Fig. 1A).
The tumor cells exhibited marked pleomorphism and contained
scattered cells resembling rhabdomyoblasts. Hyaline globules were
scattered throughout the tumor and numerous mitotic ﬁgures were
seen, as well as tumor cell necrosis. The tumor cells were diffusely
strongly positive for vimentin, focally positive for total-cytokeratin,
CK8/18, EMA, CD99, and calretinin. They were positive for P53 (N80%),
Ki-67 (~80%), NSE, CA125, and CD10. The hyaline globuleswere positive
for alpha-1-antichemotrypsin and PAS. The tumor cells were negative
for c-kit, PLAP, inhibin, CD30, AFP, beta-HCG, S-100 protein, MART-1,
CK7, CK20, CEA, CD3, CD20, LCA, myeloperoxidase, lysozyme, GFAP,
smooth muscle actin, desmin, and myoglobin. Other pathological enti-
ties such as rhabdomyosarcoma, epithelioid sarcoma, malignant mela-
noma, anaplastic dysgerminoma, and hepatoid carcinoma were ruled
out and a diagnosis of primary extra-renal MRTO was made based onA B
C D
Fig. 1. A) Sheets of large round to polygonal pleomorphic cells with atypical nuclei, conspicuou
predominantly in the upper ﬁeld (Hematoxylin & Eosin, original magniﬁcation ×200). B) Nu
retained. D) Wildtype (top) and mutated (bottom) chromatograms of the germline (left, c.164
matogram of the somatic mutationwas taken from the sequence of the reverse complement, as
clear in the forward trace.histology and immunohistochemistry (IHC); no reference was made
to SCCOHT.
Treatment and outcome
The patient underwent uneventful post-operative recovery. A CT
scan performed four weeks after maximal cytoreduction showed liver
metastases and retroperitoneal, peritoneal, and pelvic masses up to
3 cmeach. The patient received 3 cycles of combined IEP chemotherapy:
ifosfamide 1.5 g/m2 days 1–5, epirubicin 50mg/m2 on day 1 and cisplatin
70mg/m2 on day 1, without debilitating side effects, treatment delays, or
dose reduction. CT scan following chemotherapy demonstrated com-
plete resolution of all radiologic ﬁndings. However, after three additional
cycles, CT and PET–CT scans revealed disease recurrence in the liver,
retroperitoneum and pelvis. The patient received four injections of
second line weekly doxorubicin 20 mg/m2, but ﬁnally succumbed to
her disease, eight months after the initial diagnosis.
Revisting the case — immunohistochemical and mutation analysis
The identiﬁcation of SMARCA4mutations in nearly all SCCOHTs, ac-
companied by loss of expression of SMARCA4 protein as detected by
IHC (Jelinic et al., 2014; Ramos et al., 2014a; Witkowski et al., 2014),
has rendered diagnosis of this rare tumor substantially more straight-
forward. This discovery, together with the suggestion that SCCOHTs
might in fact be part of the rhabdoid tumor family led us to revisit this
case in 2014. IHC analysis of the tumor revealed immunoreactivity
with SMARCB1 (Fig. 1B), but loss of SMARCA4 expression (Fig. 1C). Sub-
sequent Sanger sequencing of the SMARCA4 gene revealed germline
(c.1641_1641delC; p.D547Efs*66) and somatic (c.1714ANT; p.K572*)Germline: c.1641_1641delC; p.D547Efs*66
Wildtype
*
Somatic:c.1714A>T; p.K572*
Wildtype
s nucleoli and abundant eosinophilic cytoplasm; numerous apoptotic bodies are evident,
clear staining of SMARCA4 is lost in the tumor cells. C) Nuclear staining for SMARCB1 is
1_1641delC; p.D547Efs*66) and somatic (right, c.1714A T; p.K572*) mutations. The chro-
the nucleotide changewas near the position of the germline deletion, and therefore not as
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established.
Discussion
The diagnosis of MRT is based on light microscopy with supportive
immunohistochemistry of SMARCB1 and SMARCA4 proteins. While
the usual genetic characteristic of MRTs is loss of the SMARCB1 protein,
those arising in the ovary more often show loss of SMARCA4 (Jelinic
et al., 2014; Ramos et al., 2014a; Witkowski et al., 2014); only two
cases have been found to show loss of SMARCB1 (Ramos et al.,
2014b). The reason for this remains unclear, but with the greatmajority
of SCCOHT/MRTO showing loss of SMARCA4 expression, it has been
proposed as a diagnostic marker for MRTO (Foulkes et al., 2014).
When presented with a tumor showing features of SCCOHT/MRTO, we
recommend the following management steps: 1) conﬁrmation of the
diagnosis by SMARCA4 staining; if SMARCA4 staining is retained, it is
unlikely MRTO (although keeping in mind that 2 cases of MRTO have
been reported with retained SMARCA4 staining and likely deleterious
mutations in SMARCA4 (Witkowski et al., 2014)). 2) Offer germ-line ge-
netic testing to rule out a transmissible SMARCA4 mutation. 2a) If a
germlinemutation is found, relevant familymembers, bothmale and fe-
male, should be counseled and tested for this mutation; male carriers
may be at risk for MRTs in other tissues, including the brain. 2b) If no
germline mutation is found, further somatic genetic testing should be
performed to conﬁrm diagnosis, since loss of SMARCA4 protein expres-
sion can occur without a mutation, and, discussed above, vice versa
(Witkowski et al., 2014).
In this case, the IHC was done post-mortem and therefore could not
have inﬂuenced management; however, given the detection of a
germline mutation, her children can now be offered testing for this
mutation and any daughters can be screened for this cancer if they are
mutation carriers, or possibly be offered preventive oophorectomy
(Berchuck et al.). In the case of unilateral localized disease, affected
germline mutation carriers may opt for a contralateral prophylactic
oophorectomy as it is theoretically possible that a new primary can-
cer could arise in the remaining ovary (Berchuck et al.). Irrespective
of the tumor site, the prognosis of MRT is extremely poor. Although
some intensive protocols with autologous bone marrow transplanta-
tion have achieved some notable successes (Distelmaier et al., 2006),
there is a desperate need for new, more effective therapies. At the
moment, the identiﬁcation of mutations in SMARCA4 as the main
cause of these tumors does not have any chemotherapeutic implica-
tions, but perhaps because of the quiescent genome of these tumors,
epigenetic therapies are a better option. Such approaches are being
actively pursued, in the hope of improving the outcome for women
afﬂicted by this rare, but highly aggressive neoplasm.
Conclusion
We describe the clinico-pathological features of a primary pure
MRTO. Although these tumors are rare, correct diagnosis is essential,due to their highly aggressive, often fatal, and possible hereditary na-
ture. Interestingly, this tumor might have been initially diagnosed as
SCCOHT, but was referred to as MRTO from the outset. At that time,
SMARCA4 alterations had not been identiﬁed as the cause of SCCOHT,
so the molecular association between MRTO and SCCOHT could not
have been made. Irrespective of the IHC or molecular links, the prior
description of a rhabdoid-cell enriched, large cell variant of SCCOHT
makes the point that MRTO and SCCOHT are histologically very similar,
if not identical. Incorporation of immunohistochemical and molecular
techniques into the work-up of probable SCCOHT/MRTO cases will
increase the number of correctly diagnosed cases and, in turn, may
provide a better insight into tumor behavior and novel treatment
options.
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